825 related articles for article (PubMed ID: 11483329)
1. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group.
Auchter RM; Scholtens D; Adak S; Wagner H; Cella DF; Mehta MP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1199-206. PubMed ID: 11483329
[TBL] [Abstract][Full Text] [Related]
2. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
Movsas B; Hu C; Sloan J; Bradley J; Komaki R; Masters G; Kavadi V; Narayan S; Michalski J; Johnson DW; Koprowski C; Curran WJ; Garces YI; Gaur R; Wynn RB; Schallenkamp J; Gelblum DY; MacRae RM; Paulus R; Choy H
JAMA Oncol; 2016 Mar; 2(3):359-67. PubMed ID: 26606200
[TBL] [Abstract][Full Text] [Related]
3. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592.
Cella D; Eton DT; Fairclough DL; Bonomi P; Heyes AE; Silberman C; Wolf MK; Johnson DH
J Clin Epidemiol; 2002 Mar; 55(3):285-95. PubMed ID: 11864800
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
[TBL] [Abstract][Full Text] [Related]
5. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.
Sause WT; Scott C; Taylor S; Johnson D; Livingston R; Komaki R; Emami B; Curran WJ; Byhardt RW; Turrisi AT
J Natl Cancer Inst; 1995 Feb; 87(3):198-205. PubMed ID: 7707407
[TBL] [Abstract][Full Text] [Related]
6. Long-term quality of life in early-stage non-small cell lung cancer patients treated with robotic stereotactic ablative radiation therapy.
Mathieu D; Campeau MP; Bahig H; Larrivée S; Vu T; Lambert L; Lavoie C; Roberge D; Doucet R; Carrier JF; Gorgos A; Fortin B; Filion E
Pract Radiat Oncol; 2015; 5(4):e365-73. PubMed ID: 25680997
[TBL] [Abstract][Full Text] [Related]
7. A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: an interim toxicity analysis of the first 100 patients.
Ball D; Bishop J; Smith J; Crennan E; O'Brien P; Davis S; Ryan G; Joseph D; Walker Q
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):267-72. PubMed ID: 7836079
[TBL] [Abstract][Full Text] [Related]
8. Cancer Trials Ireland (ICORG) 06-34: A multi-centre clinical trial using three-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer.
McDermott RL; Armstrong JG; Thirion P; Dunne M; Finn M; Small C; Byrne M; O'Shea C; O'Sullivan L; Shannon A; Kelly E; Hacking DJ
Radiother Oncol; 2018 May; 127(2):253-258. PubMed ID: 29548561
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593.
Mehta MP; Tannehill SP; Adak S; Martin L; Petereit DG; Wagner H; Fowler JF; Johnson D
J Clin Oncol; 1998 Nov; 16(11):3518-23. PubMed ID: 9817269
[TBL] [Abstract][Full Text] [Related]
10. Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy - Results of the randomized CHARTWEL trial.
Hechtner M; Krause M; König J; Appold S; Hornemann B; Singer S; Baumann M
Radiother Oncol; 2018 Feb; 126(2):283-290. PubMed ID: 29273262
[TBL] [Abstract][Full Text] [Related]
11. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Sause W; Kolesar P; Taylor S IV; Johnson D; Livingston R; Komaki R; Emami B; Curran W; Byhardt R; Dar AR; Turrisi A
Chest; 2000 Feb; 117(2):358-64. PubMed ID: 10669675
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04.
Komaki R; Seiferheld W; Ettinger D; Lee JS; Movsas B; Sause W
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):548-57. PubMed ID: 12062596
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
14. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
[TBL] [Abstract][Full Text] [Related]
15. Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: clinical phase I/II trial.
Fu XL; Jiang GL; Wang LJ; Qian H; Fu S; Yie M; Kong FM; Zhao S; He SQ; Liu TF
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):545-52. PubMed ID: 9336130
[TBL] [Abstract][Full Text] [Related]
16. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers.
Onimaru R; Shirato H; Shimizu S; Kitamura K; Xu B; Fukumoto S; Chang TC; Fujita K; Oita M; Miyasaka K; Nishimura M; Dosaka-Akita H
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):126-35. PubMed ID: 12694831
[TBL] [Abstract][Full Text] [Related]
17. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
Zehentmayr F; Söhn M; Exeli AK; Wurstbauer K; Tröller A; Deutschmann H; Fastner G; Fussl C; Steininger P; Kranzinger M; Belka C; Studnicka M; Sedlmayer F
Radiat Oncol; 2015 May; 10():121. PubMed ID: 26018527
[TBL] [Abstract][Full Text] [Related]
18. Gender differences in pretreatment quality of life in a prospective lung cancer trial.
Siddiqui F; Kohl R; Swann S; Watkins-Bruner D; Movsas B
J Support Oncol; 2008 Jan; 6(1):33-9. PubMed ID: 18257399
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
20. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
